Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2018
Price : $35 *
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 17 Apr 2016 Final results (n=65) presented at The International Liver Congress™ 2016.
- 09 Dec 2015 Status changed from not yet recruiting to completed, as reported by ClinicalTrials.gov.
- 30 Jul 2014 Planned initiation date changed from 1 Apr 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.